Brief: Neurovive says NVP015 program reaches milestone

Abliva AB

30/11/2017 07:30

Nov 30 (Reuters) - Neurovive Pharmaceutical Ab  NVP.ST : 
    * NEUROVIVE'S GENETIC MITOCHONDRIAL DISEASE PROGRAM NVP015 
REACHES 
SIGNIFICANT MILESTONE 
    * SAYS MOLECULES IN ITS NVP015 PROGRAM HAVE DEMONSTRATED 
POSITIVE 
EFFECTS IN EXPERIMENTAL MODELS OF GENETIC MITOCHONDRIAL DISEASE 
AND THAT A LEAD COMPOUND HAS BEEN SELECTED 
    * SAYS LEAD WAS SELECTED BASED ON TOLERABILITY, PLASMA 
STABILITY 
AND ORGAN DELIVERY, SPECIFICALLY TO BRAIN, AND WILL NOW BE TAKEN 
INTO FURTHER IN VIVO EXPERIMENTAL EFFICACY STUDIES AND 
PRECLINICAL DEVELOPMENT 
 
Source text for Eikon:  ID:nWkr7BKntf  
Further company coverage:  NVP.ST  
 
 ((niklas.pollard@thomsonreuters.com;))